Thiazolidinediones and inflammation

Lupus

Volumn 14, Issue 9, 2005, Pages 794-797

  Consoli, Agostino ^a,b   Devangelio, E ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b Campus Universita d'Annunzio ^*  (Italy)

Author keywords

Atherosclerosis; Cardiovascular disease; Inflammation; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C REACTIVE PROTEIN; CD40 ANTIGEN; CYTOKINE; GELATINASE B; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; LIGAND; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL NUCLEUS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE MARKER; DRUG EFFECT; HUMAN; INFLAMMATION; LIVER TOXICITY; MACROPHAGE ACTIVATION; MONOCYTE; MONONUCLEAR CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANTI-INFLAMMATORY AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 26244432068     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2223oa     Document Type: Review

References (20)

1. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. Nuclear receptors and lipid physiology: opening the X-files. Science 2001; 294: 1866-1870.
2. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001; 70: 341-367.
3. Yki-Järvinen J. Thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
4. 12,14-prostaglandin J2 through PPARγ -dependent and -independent mechanism. FASEB J 2002; 16: A1082.
5. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-86.
6. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
7. Cuzzocrea S, Pisano B, Dugo L et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation. Europ J Pharmacol 2004; 483: 79-93.
8. 12,14-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol 2003; 171: 6827-6837.
9. Ghanim H, Garg R, Aljada A et al. Suppression of nuclear factor-kB and stimulation of inhibitor kB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86:1306-1312.
10. Aljada A, Garg R, Ghanim H et al. Nuclear factor-kB suppressive and inhibitor-kB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an anti-inflammatory action? J Clin Endocrinol Metab 2001; 86: 3250-3256.
11. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004; 89: 2728-2735.
12. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
13. Marx N, Froehlich J, Siam L et al. Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003; 23: 283-288.
14. Marx N, Imbof A, Froehlich J et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003; 107: 1954-1957.
15. Satoh N, Ogawa Y, Usui T et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003; 26: 2493-2499.
16. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996; 85: 307-310.
17. Vaishnaw AK, Mcnally JD, Elkon, KB. Apoptosis in the rheumatic diseases. Arthritis Rheum 1997; 40: 1917-1927.
18. 12,14- PGJ2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000; 106: 189-197.
19. Yamasaki S, Nakashima T, Kawakami A et al. Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor γ-mediated signalling pathway. Clin Exp Immunol 2002; 129: 379-384.
20. Francois M, Richette P, Tsagris L et al. Peroxisome proliferator- activated receptorγ down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element. J Biol Chem 2004; 279: 28411-28418.